research
AnythingResearch
Industry Data & Market Research
AnythingResearch

2020 U.S. Industry Statistics & Market Research - Pharmaceutical Preparation Manufacturing


Market Size & Industry Statistics

The total U.S. industry market size for Pharmaceutical Preparation Manufacturing: Industry statistics cover all companies in the United States, both public and private, ranging in size from small businesses to market leaders. In addition to revenue, the industry market analysis shows information on employees, companies, and average firm size.

Investors, banks, and business executives use growth rates and industry trends to understand the market outlook and opportunity.

Pharmaceutical Preparation Manufacturing market size 2020
Charts and graphs can be copied to Microsoft Word and Powerpoint presentations.

Statistics 2014        2015        2016        2017        2018        2019
Market Size
(Total Sales/Revenue)


Order at top of page
Total Firms
Total Employees
Average Revenue Per Firm
Average Employees Per Firm
Average Revenue Per Employee
Statistics Source: U.S. Census, AnythingResearch Analysis of Federal Data



Market Forecast

Market forecasts show the long term industry outlook and future growth trends. The following extended five-year / six-year demand forecast projects both short-term and long-term trends.





Forecast / Industry Outlook 2020 2021 2022 2023 2024 2025
Market Forecast ($ millions)
Projected Industry Growth Rate (%)
Source: AnythingResearch Economic Analysis

Product & Services Breakdown

Research products and services in the Pharmaceutical Preparation Manufacturing industry generating sales. Note that products are broken into categories with different levels of classification.

Product Description Sales ($ millions) Percent of Total Sales

Industry Total

Medicinal And Botanical Manufacturing

Synthetic Organic Medicinal Chemicals (All Uses), Medicinal And Botanical Drugs, Chemicals, And Products, In Bulk, Alkaloid Drug

Pharmaceutical Preparation Manufacturing

Pharmaceutical Preparations, Acting On The Central Nervous System And The Sense Organs, For Human Use

Pharmaceutical Preparations, Acting On The Cardiovascular System, For Human Use

Pharmaceutical Preparations, Acting On The Respiratory System, For Human Use

Pharmaceutical Preparations, Acting On Skin, For Human Use

Pharmaceutical Preparations, Vitamin, Nutrient, And Hematinic Preparations, For Human Use

Pharmaceutical Preparations, Affecting Parasitic And Infective Diseases, For Human Use (Excluding Diagnostics)

Pharmaceutical Preparation Manufacturing, Not Categorized, Total

Biological Product (Except Diagnostic) Manufacturing

Other Biologics, Excluding Diagnostic, For Human Use

Toilet Preparation Manufacturing

Creams, Lotions And Oils, Excluding Shaving, Hair, And Deodorant

Total Miscellaneous Receipts

Resales - Sales Of Products Bought And Sold Without Further Manufacture, Processing, Or Assembly

Contract Work - Receipts For Work Done For Others On Their Materials

Miscellaneous Receipts, Including Receipts For Repair Work, Sales Of Scrap And Refuse.



U.S. Geographic Distribution: Revenue Statistics by State

Market Size by State ($ millions) indicates how the industry's competition is distributed throughout the country. State-level information can identify areas with higher and lower industry market share than average.

U.S. map by state

Pharmaceutical Preparation Manufacturing Industry Price Trends

Rise and fall in market prices are affectedd by supply, demand, and the cost of goods/services sold. Higher demand or COGS will put upward price pressure on prices. Higher competition among Pharmaceutical Preparation Manufacturing companies will put a downward pressure on prices. The chart shows how prices are changing within the industry, month-to-month over the last three years.

example price index trendline

Income Statement (Average Financial Metrics)

Financial metrics provide a snapshot view of a benchmark "average" company. Key business metrics show revenue and operating costs. The data collected covers both public and private companies.

Industry AveragePercent of Sales
(Industry Benchmark)
Total Revenue

Order at top of page
Operating Revenue
Cost of Goods Sold
Gross Profit

Operating Expenses
Pension, profit sharing plans, stock, annuity
Repairs
Rent paid on business property
Charitable Contributions
Depletion
Domestic production activities deduction
Advertising
Compensation of officers
Salaries and wages
Employee benefit programs
Taxes and Licenses
Bad Debts
Depreciation
Amortization
Other Operating Expenses
Total Operating Expenses
Operating Income
Non-Operating Income
EBIT (Earnings Before Interest and Taxes)
Interest Expense
Earnings Before Taxes
Income Tax
Net Profit
Net Income
 
Source: AnythingResearch Analysis of U.S. federal statistics




Financial Ratio Analysis

Financial ratio information can be used to benchmark how a Pharmaceutical Preparation Manufacturing company compares to its peers. Accounting statistics are calculated from the industry-average for income statements and balance sheets.

Profitability & Valuation RatiosIndustry Average
Company valuation can be measured based on the firm's own performance, as well as in comparison against its industry competitors. These metrics show how the average company in the Pharmaceutical Preparation Manufacturing industry is performing.
Profit Margin
Gross Profit Margin, Operating Profit Margin, and Net Profit Margin. Show company earnings relative to revenues.
Return on Equity (ROE)
Return on Equity (ROE) is net income as a percentage of shareholders' equity. Shareholders' Equity is defined as the company's total assets minus total liabilities. ROE shows how much profits a company generates with the money shareholders invested (or with retained earnings).
Return on Assets (ROA)
Return on Assets (ROA) is net income relative to total assets. The market research on Pharmaceutical Preparation Manufacturing measures how efficiently the company leverages its assets to generate profit. ROA is calculated as Net Income divided by Total Assets.


Liquidity RatiosIndustry Average
Bankers and suppliers use liquidity to determine creditworthiness and identify potential threats to a company's financial viability.
Current Ratio
Measures a firm's ability to pay its debts over the next 12 months.
Quick Ratio (Acid Test)
Calculates liquid assets relative to liabilities, excluding inventories.


Efficiency Ratios - Key Performance IndicatorsIndustry Average
Measure how quickly products and services sell, and effectively collections policies are implemented.
Receivables Turnover Ratio
If this number is low in your business when compared to the industry average in the research report, it may mean your payment terms are too lenient or that you are not doing a good enough job on collections.
Average Collection Period
Based on the Receivables Turnover, this estimates the collection period in days. Calculated as 365 divided by the Receivables Turnover
Inventory Turnover
A low turnover rate may point to overstocking, obsolescence, or deficiencies in the product line or marketing effort.
Fixed-Asset Turnover
Generally, higher is better, since it indicates the business has less money tied up in fixed assets for each dollar of sales revenue.



Compensation & Salary Surveys for Employees

Compensation statistics provides an accurate assessment of industry-specific jobs and national salary averages. This information can be used to identify which positions are most common, and high, low, and average annual wages.

TitlePercent of WorkforceBottom Quartile Average (Median) SalaryUpper Quartile
Management Occupations 11%

Order at top of page
Chief Executives0%
General and Operations Managers2%
Business and Financial Operations Occupations 8%
Business Operations Specialists 7%
Architecture and Engineering Occupations 6%
Life, Physical, and Social Science Occupations 16%
Life Scientists 6%
Physical Scientists 6%
Chemists and Materials Scientists 6%
Chemists 6%
Office and Administrative Support Occupations 8%
Production Occupations 32%
Other Production Occupations 26%
Packaging and Filling Machine Operators and Tenders 9%
Packaging and Filling Machine Operators and Tenders 9%
Source: Bureau of Labor Statistics


Pharmaceutical Preparation Manufacturing Competitor Landscape & Key Companies [PREMIUM]

The most influential companies in the Pharmaceutical Preparation Manufacturing industry and adjacent industries either have large market share or are developing new business models and methods that could disrupt the status quo. We look at leading and emerging companies in the Pharmaceutical Preparation Manufacturing industry and adjacent sectors:

Market Leaders:
Direct Competitors

Companies with the largest market share, focused in this industry
Market leaders:
Diversified Competitors

Largest companies that have diversified operations in this and other industries
Innovators:
Direct Competitors

Innovative, Emerging, and Disruptive Companies that may influence the future direction of the industry.
Innovators:
Diversified Competitors

Innovators and Disruptors in adjacent industries that may also affect the Pharmaceutical Preparation Manufacturing industry.
Source:
IncFact




Executive Briefings

   Our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. We believe that key competitive factors that will affect the development and commercial success of our product candidates are efficacy, safety, tolerability, reliability, price and reimbursement level. Many of our potential competitors, including many of the organizations named below, have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of product candidates, obtaining the FDA’s and other regulatory approvals of products and the commercialization of those products. Accordingly, our competitors may be more successful than we may be in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors’ drugs may be more effective, or more effectively marketed and sold, than any drug we may commercialize and may render our product candidates obsolete or non-competitive before we can recover the expenses of developing and commercializing any of our product candidates. We anticipate that we will face intense and increasing competition as new drugs enter the market and advanced technologies become available. Further, the development of new treatment methods for the conditions we are targeting could render our drugs non-competitive or obsolete.   COVID-19 Vaccine Development Projects   The activity for developing vaccines for COVID-2019 is competitive and includes companies and academic institutions. GlaxoSmithKline (GSK) / Clover Biopharmaceuticals, Novavax, Altimmune, Vaxart, Generex Biotechnology, Vaxil Bio, iBio, Baylor College of Medicine / New York Blood Center, University of Queensland, University of Saskatchewan, University of Oxford / Advent Srl are working on protein-based vaccines.   Smallpox vaccines and antivirals   A number of companies are marketing or developing vaccines and treatments for smallpox, including Emergent BioSolutions, Bavarian Nordic, SIGA Technologies and Chimerix. Emergent BioSolutions markets ACAM2000, which is a replicating vaccinia vaccine for the prevention of smallpox.  Bavarian Nordic received FDA approval and markets Jynneos® (or Modified Virus Ankara, strain BN or MVA-BN), which is a non-replicating vaccinia virus vaccine for the prevention of smallpox and monkeypox. SIGA received FDA approval and markets TPOXX® (tecovirimat), which is an antiviral for smallpox.    26      CNS Condition Therapeutics   The market for therapies to treat FM, PTSD and other CNS conditions is well developed and populated with established drugs marketed by large and small pharmaceutical, biotechnology and generic drug companies.   A number of companies are developing prescription medicines for FM, including Aptinyx (NYX-2925), Innovative Medical Concepts (celecoxib and famciclovir or IMC-1) and Axsome (eseboxetine or AXS-14).   PTSD   In PTSD GlaxoSmithKline (Paxil®) and Pfizer (Zoloft®) developed and market Paxil® and Zoloft®, respectively for PTSD that are approved by the FDA.   Certain other companies and institutions are known to be developing prescription medications for PTSD, including Bionomics (BNC-201), Otsuka/Lundbeck (Rexulti® [brexpiprazole]), Uniformed Services University of the Health Sciences (riluzole), the Multidisciplinary Association of Psychedelic Studies (methylenedioxymethamphetamine [MDMA]) and Aptinyx (NYX-783). Brainsway Ltd., a medical device company, is currently recruiting patients for a pivotal Phase 3 trial using a deep transcranial magnetic stimulation device for treatment of PTSD. A number of other companies and institutions have or may be developing prescription medications for PTSD, including: Mt. Sinai Hospital and Medical School in New York City is developing ketamine which is in Phase 2 and targets the NMDA receptor, Azevan Pharmaceuticals is developing SRX246 which is in Phase 2 and targets the vasopressin V1A receptor, University of California, San Diego (UCSD) is developing losartan which is in Phase 2 and is an angiotensin receptor blocker (ARB), Massachusetts General Hospital (MGH), University of California, San Francisco (UCSF) are developing oxytocin which is in Phase 2 and targets the oxytocin receptor, Nobilis Therapeutics is developing NBTX-001, a noble gas, which is in Phase 2, EpiVario is developing inhibitors of Acetyl CoA synthetase, which is in Phase 1 and Seelos Therapeutics (recently merged with Apricus Biosciences) is developing an intranasal racemic ketamine to treat PTSD and major depressive disorder (MDD).   Several companies have clinical candidates for which PTSD is being considered as a secondary indication.   Agitation in Alzheimer’s Disease   Additionally, a number of companies are developing prescription medicines for AAD, including Otsuka/Lundbeck (Rexulti® or brexpiprazole), Avanir/Otsuka (deudextromethorphan), Axsome (dextromethorphan/buproprion) and InterCellular (lumateperone). Lumateperone is in Phase 3 for treating behavioral disturbances associated with dementia and was recently approved as CAPLYTA® for the treatment of schizophrenia.   Although a number of companies are marketing or developing prescription medicines for sleep disorders, including Merck Tonix Pharmaceuticals Holding

Government Contracts

In 2020, the federal government spent a total of $3,238,983,457 on Pharmaceutical Preparation Manufacturing. It has awarded 4823 contracts to 608 companies, with an average value of $5,327,275 per company.   

Most Recent Contracts Date Total Award Amount
UNITED THERAPEUTICS CORPORATION
1040 Spring St
Silver Spring, MD
Sep 26, 2020$33,808
CSL BEHRING L.L.C.
1020 1st Ave
King Of Prussia, PA
Sep 25, 2020$6,544
RLS USA INC.
3350 N Ridge Ave
Arlington Heights, IL
Sep 25, 2020$656,250
BAUSCH HEALTH US, LLC
400 Somerset Corporate Blvd
Bridgewater, NJ
Sep 25, 2020$20,156
QUVA PHARMA, INC.
1075 W Park One Dr Ste 100
Sugar Land, TX
Sep 25, 2020$86,243
MCKESSON CORPORATION
6555 State Highway 161
Irving, TX
Sep 25, 2020$24,047




Related Reports

Can't find what you're looking for? We have over a thousand market research reports. Ask us and an analyst will help you find what you need.

Industries Related to Pharmaceutical Preparation Manufacturing

Pharmaceutical Preparation Manufacturing